Efficacy of hippocampal fetal cell (HFC) grafting for restraining spontaneous recurrent motor seizures (SRMS) in chronic temporal lobe epilepsy (TLE) is unknown. We investigated both survival and anti-seizure effects of 5′-bromodeoxyuridine (BrdU) labeled embryonic day 19 (E19) HFC grafts pretreated with different neurotrophic factors and a caspase inhibitor. Grafts were placed bilaterally into the hippocampi of F344 rats exhibiting kainate (KA) induced chronic TLE, where the frequency of SRMS varied from 3.0 to 3.5 seizures/8-h duration. The first group received standard (untreated) HFC grafts, the second group received HFC grafts pretreated and transplanted with brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and caspase inhibitor Ac-YVADcmk (BNC-treated HFC grafts), the third group received HFC grafts pretreated and transplanted with fibroblast growth factor-2 (FGF-2) and caspase inhibitor Ac-YVAD-cmk (FC-treated HFC grafts), and the fourth group served as epilepsy-only controls. Epileptic rats receiving standard HFC grafts exhibited 119% increase in the frequency of SRMS at 2 months post-grafting consistent with 125% increase in seizure frequency observed in epilepsy-only controls during the same period. However, in epileptic rats receiving HFC grafts treated with BNC or FC, the frequency of SRMS was 33-39% less than their pre-transplant scores and 73-76% less than rats receiving standard HFC grafts or epilepsy-only rats. The yield of surviving neurons was equivalent to 30% of injected cells in standard HFC grafts, 57% in HFC grafts treated with BNC and 98% in HFC grafts treated with FC. Thus, standard HFC grafts survive poorly in the chronically epileptic hippocampus and fail to restrain the progression of chronic TLE. In contrast, HFCs treated and grafted with BNC or FC survive robustly in the chronically epileptic hippocampus, considerably reduce the frequency of SRMS and blunt the progression of chronic TLE.
Introduction
Epilepsy affects nearly 1-2% of the general population (Ang et al., 2006) and 40% of patients suffering from epilepsy have chronic temporal lobe epilepsy (TLE). The TLE is epitomized by the progressive expansion of spontaneous recurrent motor seizures (SRMS) that arise from the limbic system regions, especially the hippocampus (Engel, 1998; French et al., 1993) . The TLE with hippocampal sclerosis, one of the most prevailing types of partial seizure disorders (Engel, 1998; Wieser and Hane, 2004) , is generally linked to an initial precipitating event such as febrile convulsions, head trauma, status epilepticus (SE) or encephalitis (Harvey et al., 1997; Fisher et al., 1998; Cendes, 2004) . The hippocampal sclerosis is characterized by pervasive neuronal loss in the dentate hilus and the CA1 and CA3 subfields, deviant mossy fiber sprouting into the dentate supragranular layer and deeply diminished dentate neurogenesis (Sutula et al., 1989; Dalby and Mody, 2001; Buckmaster et al., 2002; Hattiangady et al., 2004) . Thirty-five percent of the people with TLE have chronic seizures that are resistant to antiepileptic drugs (Engel, 2001; Litt et al., 2001; McKeown and McNamara, 2001 ) and most TLE patients have learning and memory impairments and depression, likely due to the persistence of seizures (Devinsky, 2004; Detour et al., 2005) . Thus, careful investigation of alternative therapies that have the potential for both reversing the epileptogenic circuitry and suppressing chronic epileptic seizures after the inception of TLE is needed.
Grafting of hippocampal fetal cells (HFCs) into the hippocampus may be effective for suppressing chronic seizures in TLE because these grafts have been found to be efficacious for healing hippocampal injury (Shetty and Turner, 1996; Turner and Shetty, 2003) . Indeed, previous studies have shown that HFCs exhibit enhanced integration into the injured adult hippocampus when placed early after the injury (Shetty and Turner, 1995a, 2000; Zaman et al., 2000) . Furthermore, these grafts facilitate restitution of the disrupted circuitry and restrain the abnormal synaptic reorganization that typically crops up in the hippocampus after injury (Shetty and Turner, 1997a,b; Shetty et al., 2000 Shetty et al., , 2005 . These results are clearly encouraging for application of HFC grafting for conditions such as
